Page 27 - San Antonio Breast Cancer Symposium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Low-dose olanzapine has practice-defining implications for controlling CINV

Low-dose olanzapine has practice-defining implications for controlling CINV
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesBymatthew shinkleJyoti bajpaiMindy valcarcelTata memorial centreSan antonio breast cancer symposium

Study Underscores Value of Early Fertility Counseling for Breast Cancer Patients

Younger age, embryo/oocyte cryopreservation at diagnosis tied to an increased chance of pregnancy

United statesSouth koreaSan antonioNuevo leóxSoult ukpyolsiHatem azimHee jeong kimMike bassettSchool of medicineBreast cancer centerUniversity of ulsan asan medical centerSan antonio breast cancer symposiumAsan medical center

MEDSIR presents promising results at SABCS 2023: ATRACTIB and DEBBRAH trials hold potential to improve the lives of advanced breast cancer patients

The novel combination therapy with atezolizumab and bevacizumab added to chemotherapy as first-line treatment in the ATRACTIB trial demonstrates significant.

United statesMarta vazDoutor fernando fonsecaCajal university hospitalSan antonio breast cancer symposiumMedical oncologistLow advanced breast cancerHospital professor doutor fernando fonsecaHuman epidermal growth factorHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveriesOlls and research

Tailored interventions needed to address catastrophic financial burdens of cancer care

Tailored interventions needed to address catastrophic financial burdens of cancer care
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesMindy valcarcelFumiko chinoByjennifer southallMemorial sloan kettering cancer centerSan antonio breast cancer symposiumOncology peer perspective board

Tucatinib Plus T-DM1 Improves PFS Over T-DM1 Alone in Advanced HER2+ Breast Cancer

Adding tucatinib to T-DM1 prolonged PFS in a phase 3 trial of patients with previously treated, advanced, HER2-positive breast cancer. Adding tucatinib to T-DM1 prolonged PFS in a phase 3 trial of patients with previously treated, advanced, HER2-positive breast cancer.

United statesSan antonioSaraa hurvitzFred hutchinson cancer centerSan antonio breast cancer symposium